Percutaneous Sclerotherapy of Venous Malformations of the Hand: A Multicenter Analysis.
Cardiovasc Intervent Radiol
; 44(10): 1543-1550, 2021 Oct.
Article
em En
| MEDLINE
| ID: mdl-34286368
ABSTRACT
PURPOSE:
To evaluate the safety and outcome of percutaneous sclerotherapy for treating venous malformations (VMs) of the hand. MATERIALS ANDMETHODS:
A retrospective multicenter trial of 29 patients with VMs primarily affecting the hand, including wrist, carpus, and/or fingers, treated by 81 percutaneous image-guided sclerotherapies using ethanol gel and/or polidocanol was performed. Clinical and imaging findings were assessed to evaluate clinical response, lesion size reduction, and complication rates. Substratification analysis was performed with respect to the Puig's classification, the sclerosing agent, the injected volume of the sclerosant, and to previously performed treatments.RESULTS:
The mean number of procedures per patient was 2.8 (± 2.2). Last follow-up (mean = 9.2 months) revealed a partial relief of symptoms in 78.9% (15/19), while three patients (15.8%) presented symptom-free and one patient (5.3%) with no improvement. Post-treatment imaging revealed an overall objective response rate of 88.9%. Early post-procedural complications occurred after 5/81 sclerotherapies (6.2%) and were entirely resolved by conservative means. Type of VM (Puig's classification) as well as sclerosing agent had no impact on clinical response (p = 0.85, p = 0.11) or complication rates (p = 0.66, p = 0.69). The complication rates were not associated with the sclerosant volume injected (p = 0.76). In addition, no significant differences in clinical success (p = 0.11) or complication rates (p = 0.89) were detected when comparing patients with history of previous treatments compared to therapy-naive patients.CONCLUSION:
Percutaneous sclerotherapy is both safe and effective for treating VMs of the hand. Even patients with history of previous treatments benefit from further sclerotherapy showing similar low complication rates to therapy-naive patients. LEVEL OF EVIDENCE Level 4, Retrospective study.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Soluções Esclerosantes
/
Escleroterapia
Idioma:
En
Ano de publicação:
2021
Tipo de documento:
Article